ALISON trial data presented at ASCO 2025 demonstrates successful induction of tumor-directed immune responses in high-risk ovarian cancer

What we doOur approachPipelineTechnologyPatient Stories
About usManagementBoardClinical Advisory BoardCareers
Newsroom
InvestorsPress releases

Back
ALISON trial data presented at ASCO 2025 demonstrates successful induction of tumor-directed immune responses in high-risk ovarian cancer
 8:00:00 AM

Keep reading
Data presented at EHA strengthens Mendus’ programs in myeloid leukemiasRead